Interestingly, AML patients with heterozygous TP53 mutations have shown similar responses to therapy as those harboring wt TP53 (Barnoud et al., 2021; Kennedy and Lowe, 2022; Daver et al., 2023a). This evidence concerns the gene TP53 and acute myeloid leukemia.